Is Tenaya Therapeutics Stock a Good Investment?
Tenaya Therapeutics Investment Advice | TNYA |
- Examine Tenaya Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Tenaya Therapeutics' leadership team and their track record. Good management can help Tenaya Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Tenaya Therapeutics' business and its evolving consumer preferences.
- Compare Tenaya Therapeutics' performance and market position to its competitors. Analyze how Tenaya Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Tenaya Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Tenaya Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Tenaya Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Tenaya Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Tenaya Therapeutics Stock
Researching Tenaya Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 74.0% of the company shares are owned by institutional investors. The book value of Tenaya Therapeutics was at this time reported as 1.42. The company recorded a loss per share of 1.44. Tenaya Therapeutics had not issued any dividends in recent years.
To determine if Tenaya Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Tenaya Therapeutics' research are outlined below:
| Tenaya Therapeutics is way too risky over 90 days horizon | |
| Tenaya Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (124.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tenaya Therapeutics currently holds about 180.92 M in cash with (102.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Tenaya Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Tenaya shares retain Buy rating, price target on trial update |
Tenaya Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Tenaya Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tenaya Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Tenaya Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Tenaya Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-09 | 2024-06-30 | -0.39 | -0.34 | 0.05 | 12 | ||
2023-08-09 | 2023-06-30 | -0.5 | -0.45 | 0.05 | 10 | ||
2024-11-07 | 2024-09-30 | -0.3671 | -0.3 | 0.0671 | 18 | ||
2023-11-08 | 2023-09-30 | -0.47 | -0.39 | 0.08 | 17 | ||
2022-11-10 | 2022-09-30 | -0.64 | -0.74 | -0.1 | 15 | ||
2022-05-11 | 2022-03-31 | -0.64 | -0.75 | -0.11 | 17 | ||
2023-05-10 | 2023-03-31 | -0.56 | -0.43 | 0.13 | 23 | ||
2021-09-08 | 2021-06-30 | -7.17 | -13.26 | -6.09 | 84 |
Tenaya Therapeutics Target Price Consensus
Tenaya target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Tenaya Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 9 | Strong Buy |
Most Tenaya analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Tenaya stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Tenaya Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationTenaya Therapeutics Target Price Projection
Tenaya Therapeutics' current and average target prices are 3.57 and 21.33, respectively. The current price of Tenaya Therapeutics is the price at which Tenaya Therapeutics is currently trading. On the other hand, Tenaya Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Tenaya Therapeutics Market Quote on 2nd of December 2024
Target Price
Analyst Consensus On Tenaya Therapeutics Target Price
Tenaya Therapeutics Analyst Ratings
Tenaya Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Tenaya Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Tenaya Therapeutics' financials, market performance, and future outlook by experienced professionals. Tenaya Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Tenaya Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tenaya Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tenaya Therapeutics backward and forwards among themselves. Tenaya Therapeutics' institutional investor refers to the entity that pools money to purchase Tenaya Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fmr Inc | 2024-09-30 | 1.3 M | Geode Capital Management, Llc | 2024-09-30 | 1.3 M | State Street Corp | 2024-09-30 | 1.1 M | Euclidean Capital Llc | 2024-09-30 | 1 M | Schonfeld Strategic Advisors Llc | 2024-09-30 | 917.4 K | Alphabet Inc | 2024-09-30 | 915.7 K | Abrdn Plc | 2024-09-30 | 550.7 K | Stepstone Group Llc | 2024-09-30 | 462.2 K | Northern Trust Corp | 2024-09-30 | 444.8 K | Column Group Llc | 2024-09-30 | 9.4 M | Ra Capital Management, Llc | 2024-09-30 | 7 M |
Tenaya Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 282.82 M.Market Cap |
|
Tenaya Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.73) | (0.76) | |
| Return On Capital Employed | (0.89) | (0.93) | |
| Return On Assets | (0.73) | (0.76) | |
| Return On Equity | (0.89) | (0.85) |
Determining Tenaya Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Tenaya Therapeutics is a good buy. For example, gross profit margin measures Tenaya Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Tenaya Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Tenaya Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tenaya Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Tenaya Therapeutics' management manipulating its earnings.
Evaluate Tenaya Therapeutics' management efficiency
Tenaya Therapeutics has return on total asset (ROA) of (0.4594) % which means that it has lost $0.4594 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8449) %, meaning that it created substantial loss on money invested by shareholders. Tenaya Therapeutics' management efficiency ratios could be used to measure how well Tenaya Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of December 2, 2024, Return On Tangible Assets is expected to decline to -0.76. In addition to that, Return On Capital Employed is expected to decline to -0.93. At present, Tenaya Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 293.9 M, whereas Non Current Assets Total are forecasted to decline to about 50.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.70 | 1.12 | |
| Tangible Book Value Per Share | 1.70 | 1.14 | |
| Enterprise Value Over EBITDA | (1.68) | (1.76) | |
| Price Book Value Ratio | 1.71 | 1.80 | |
| Enterprise Value Multiple | (1.68) | (1.76) | |
| Price Fair Value | 1.71 | 1.80 | |
| Enterprise Value | 205.8 M | 195.5 M |
The strategic vision of Tenaya Therapeutics management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Beta 2.347 |
Basic technical analysis of Tenaya Stock
As of the 2nd of December, Tenaya Therapeutics has the Semi Deviation of 4.68, risk adjusted performance of 0.0816, and Coefficient Of Variation of 1053.23. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tenaya Therapeutics, as well as the relationship between them.Tenaya Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tenaya Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tenaya Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tenaya Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tenaya Therapeutics' Outstanding Corporate Bonds
Tenaya Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tenaya Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tenaya bonds can be classified according to their maturity, which is the date when Tenaya Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Tenaya Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Tenaya Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0816 | |||
| Market Risk Adjusted Performance | 0.3252 | |||
| Mean Deviation | 5.74 | |||
| Semi Deviation | 4.68 | |||
| Downside Deviation | 5.0 | |||
| Coefficient Of Variation | 1053.23 | |||
| Standard Deviation | 7.55 | |||
| Variance | 57.01 | |||
| Information Ratio | 0.0767 | |||
| Jensen Alpha | 0.4207 | |||
| Total Risk Alpha | (0.55) | |||
| Sortino Ratio | 0.1159 | |||
| Treynor Ratio | 0.3152 | |||
| Maximum Drawdown | 38.23 | |||
| Value At Risk | (6.88) | |||
| Potential Upside | 12.11 | |||
| Downside Variance | 25.0 | |||
| Semi Variance | 21.88 | |||
| Expected Short fall | (8.95) | |||
| Skewness | 1.29 | |||
| Kurtosis | 2.2 |
| Risk Adjusted Performance | 0.0816 | |||
| Market Risk Adjusted Performance | 0.3252 | |||
| Mean Deviation | 5.74 | |||
| Semi Deviation | 4.68 | |||
| Downside Deviation | 5.0 | |||
| Coefficient Of Variation | 1053.23 | |||
| Standard Deviation | 7.55 | |||
| Variance | 57.01 | |||
| Information Ratio | 0.0767 | |||
| Jensen Alpha | 0.4207 | |||
| Total Risk Alpha | (0.55) | |||
| Sortino Ratio | 0.1159 | |||
| Treynor Ratio | 0.3152 | |||
| Maximum Drawdown | 38.23 | |||
| Value At Risk | (6.88) | |||
| Potential Upside | 12.11 | |||
| Downside Variance | 25.0 | |||
| Semi Variance | 21.88 | |||
| Expected Short fall | (8.95) | |||
| Skewness | 1.29 | |||
| Kurtosis | 2.2 |
Consider Tenaya Therapeutics' intraday indicators
Tenaya Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tenaya Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Tenaya Therapeutics Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 17th of September 2024 Other Reports | ViewVerify |
Tenaya Stock media impact
Far too much social signal, news, headlines, and media speculation about Tenaya Therapeutics that are available to investors today. That information is available publicly through Tenaya media outlets and privately through word of mouth or via Tenaya internal channels. However, regardless of the origin, that massive amount of Tenaya data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tenaya Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tenaya Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tenaya Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tenaya Therapeutics alpha.
Tenaya Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Tenaya Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Tenaya Therapeutics Corporate Management
| Deepak MD | Chairman Founder | Profile | |
| Saptarsi MD | Scientific Founder | Profile | |
| Sheng Ding | Scientific Founder | Profile | |
| Benoit Bruneau | Scientific Founder | Profile | |
| Timothy Hoey | Chief Officer | Profile | |
| Leone MBA | Chief Officer | Profile | |
| Chihiro Saito | Senior Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenaya Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Tenaya Stock refer to our How to Trade Tenaya Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tenaya Therapeutics. If investors know Tenaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tenaya Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.44) | Return On Assets (0.46) | Return On Equity (0.84) |
The market value of Tenaya Therapeutics is measured differently than its book value, which is the value of Tenaya that is recorded on the company's balance sheet. Investors also form their own opinion of Tenaya Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tenaya Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tenaya Therapeutics' market value can be influenced by many factors that don't directly affect Tenaya Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Tenaya Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Tenaya Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tenaya Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.